Compare Levi Strauss & Co. (LEVI) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Novavax Inc — how do they compare? Levi Strauss & Co. trades at $18.69 (market cap $7.31B), while Novavax Inc trades at $12.69 (market cap $1.82B). The key difference: Levi Strauss & Co. is far larger — about 4× Novavax Inc's market cap, and Levi Strauss & Co. pays a 3.36% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 70 Days and Novavax Inc for 59 Days on average.
| LEVI | NVAX | |
|---|---|---|
Market Cap | $7.31B | $1.82B |
Volume | 13,683,095 | 6,198,505 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $12.56 |
52-Week Low | $17.92 | $6.22 |
Typical Hold Time | 70 Days | 59 Days |
Enterprise Value | $8.86B | $1.39B |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $18.70, down 4.15% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 12.53 and consistent earnings beats, including Q3 2026 EPS of $0.48 versus $0.36 expected. Revenue for 2025 was $6.28 billion with a net income margin of 9.2%. Recent news highlights a new CFO appointment and positive analyst expectations for Q3 earnings.
The outlook is positive with a consensus price target of $29.00, implying 55% upside, supported by 78.95% analyst buy ratings. Risks include competitive pressures and recent cybersecurity incidents. The stock's valuation and earnings momentum present a compelling opportunity, though technical weakness warrants monitoring.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
